Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Forecast Data Period | 2026 - 2031 |
| Historical Data Period | 2020 - 2024 |
| Base Year Market Size (2025) | USD 89.98 Million |
| Market Size (2026) | USD 95.95 Million |
| Market Size (2031) | USD 132.33 Million |
| Growth Rate (2026 - 2031) | 6.64% CAGR |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
UK Diabetes Devices Market Analysis by Mordor Intelligence
The UK diabetes devices market size in 2026 is estimated at USD 95.95 million, growing from 2025 value of USD 89.98 million with 2031 projections showing USD 132.33 million, growing at 6.64% CAGR over 2026-2031.
The COVID-19 pandemic had a substantial impact on the United Kingdom's diabetes care devices. According to The British Diabetic Association, 'The pandemic has had, and continues to have, a huge impact on our society. However research and data have shown that people with diabetes have been disproportionately affected by COVID-19, particularly in terms of poorer outcomes when contracting the virus. That's why preventing or delaying cases of type 2 diabetes is more important than ever before.'
The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the diabetes care device market's growth.
The rate of newly diagnosed cases of Type 1 and Type 2 diabetes is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic care products. According to The British Diabetic Association, Diabetes prevalence 2021 data shows an increase in the number of people living with a diabetes diagnosis in the UK: an increase of more than 150,000 from 2020. It is estimated that more than 13.6 million people are at increased risk of type 2 diabetes in the UK. At this rate, the number of people with diabetes, including the undiagnosed population, is expected to rise to 5.5 million by 2030.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
UK Diabetes Devices Market Trends and Insights
Continuous Glucose Monitoring Segment is Expected to Witness a Healthy Growth Rate Over the Forecast Period
The continuous Glucose Monitoring Segment recorded more than USD 1.8 billion in revenue in the current year, which is expected to register further with a CAGR of more than 11.3% during the forecast period.
To use a CGM, a small sensor is inserted into the abdomen or arm with a tiny plastic tube known as a cannula penetrating the top layer of skin. An adhesive patch holds the sensor in place, allowing it to take glucose readings in interstitial fluid throughout the day and night. Generally, the sensors must be replaced every 7 to 14 days. A small, reusable transmitter connected to the sensor allows the system to send real-time readings wirelessly to a monitor device that displays blood glucose data. Some systems contain a dedicated monitor, and some display the information via a smartphone app.
Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated to the transmitter. Sensors are the most important part of continuous glucose monitoring devices. Researchers are trying to find and develop alternatives to electrochemical-based glucose sensors and create more affordable, minimally invasive, and user-friendly CGM sensors. Optical measurement is a promising platform for glucose sensing. Some technologies with high potential in continuous glucose sensing are reported, including spectroscopy, fluorescence, holographic technology, etc. Eversense, a CGM sensor based on fluorescence sensing developed by Senseonics Company, presents a much longer lifespan than electrochemical sensors. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period.
The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient. Type-1 diabetic patients need to check their blood glucose levels regularly to monitor their blood glucose levels and adjust the insulin dosing accordingly. The current CGM devices show a detailed representation of blood glucose patterns and tendencies compared to a routine check of glucose levels at set intervals. Furthermore, the current continuous glucose monitoring devices can either retrospectively display the trends in blood glucose levels by downloading the data or give a real-time picture of glucose levels through receiver displays. Continuous glucose monitoring devices are becoming cheaper with the advent of new technologies, like cell phone integration, which is likely to drive the segment growth during the forecast period.
Insulin cartridges in reusable pens occupied the highest share in the management devices segment in the current year
Insulin cartridges in reusable pens occupied the highest market share of about 51% in the management devices segment in the current year.
Insulin cartridges in reusable pens are an upgraded version of insulin vials. Most types of insulins are manufactured in the form of cartridges, making them easily accessible. These devices comprise the functional benefits of reusable pens and are cost-effective, as these cartridges are less expensive compared to disposable insulin pens in the long run. Due to the increasing demand for insulin cartridges, most insulin device manufacturers produce reusable insulin pens compatible with various manufacturers' cartridges.
These insulin cartridges are considered more consumer-friendly, as they are smaller and less noticeable than the classic vial-and-syringe. These devices are also more portable for consumers on the go. Open cartridges do not need to be refrigerated, making storage easy for consumers. Thus, cartridges are the most cost-effective insulin use, as reusable pens are a one-time investment, unlike disposable pens.
The National Service Framework (NSF) program is improving services by setting national standards to drive service quality and tackle variations in care. The Association of British HealthTech Industries (ABHI) launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind. The ABHI group is for any health technology company interested in diabetes care, from CGM and insulin pumps to apps. Such advantages helped adopt these products in the United Kingdom market.
Competitive Landscape
The UK diabetes devices market is semi-consolidated, with few significant and generic players. Manufacturers drove constant innovations to compete in the market. The major players, such as Abbott and Medtronic, underwent many mergers, acquisitions, and partnerships to establish market dominance while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. The manufacturers of insulin delivery devices are spending a massive amount on the R&D of the devices.
UK Diabetes Devices Industry Leaders
Insulet Corporation
Roche Diabetes Care
Abbott Diabetes Care
Dexcom Inc.
Medtronic PLC
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
NHS led commissioning and procurement creates whitespace for monitoring and automated insulin delivery adoption beyond intensive insulin users, particularly through structured expansion of continuous glucose monitoring (CGM) into type 2 diabetes pathways. NHS England began a 5-year phased rollout of Hybrid Closed Loop systems on 1 April 2024, and local systems are issuing implementation playbooks that translate national direction into service delivery (for instance, NHS North Central London issued a CGM implementation guide for people living with type 2 diabetes in May 2026). This combination of national rollouts and integrated care system execution favors suppliers that can support training, onboarding, and ongoing clinical support at scale in hospital/clinic and home/personal settings.
A second opportunity area is the shift toward large, multi-year procurement frameworks that bundle devices, consumables, and related services, raising the stakes for interoperability, supply assurance, and total-cost offers across CGM, insulin pumps, and HCL components. NHS Supply Chain activity points to longer-duration frameworks (including market engagement for an open framework spanning insulin pumps, CGM, HCL components, and associated services), and procurement actions in November 2025 awarded a multi-supplier contract for diabetes technology supply. For manufacturers and distributors active in the United Kingdom, positioning product portfolios and evidence packages to align with NICE and NHS pathways, while demonstrating compatibility across connected ecosystems (sensor, pump, software, and services), is becoming a primary route to expanding access and competing for national and regional tenders.
Recent Industry Developments
- May 2026: Insulet updated its 2026 outlook and highlighted continued adoption momentum in the United Kingdom as part of its broader automated insulin delivery franchise performance. The disclosure reinforced the UK as an active conversion market for tubeless pump systems and supports continued competitive emphasis on expanding eligible patient access through NHS pathways.
- February 2025: NICE published recommendations for hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes. The guidance strengthened the reimbursement and adoption framework for integrated pump and continuous glucose monitoring ecosystems, shaping supplier requirements around clinical evidence and service support.
- June 2024: Insulet announced the full commercial launch of Omnipod 5 in the United Kingdom with expanded sensor integrations, including compatibility with Dexcom G6 and Abbott FreeStyle Libre 2 Plus. The multi-sensor approach increased choice for users and clinicians and intensified competition around interoperability in AID platforms.
Research Methodology Framework and Report Scope
Market Definition and Coverage
This market covers diabetes devices sold and used in the United Kingdom for monitoring glucose and delivering insulin, measured in revenue terms for a defined year set and forecast window.
Scope exclusions: Diabetes drugs, lab testing services, and general wellness wearables that are not used for diabetes monitoring or insulin delivery are excluded.
Segmentation Overview
- Management Devices
- Insulin Pump
- Technology
- Tethered Insulin Pump
- Tubeless Insulin Pump
- Component
- Insulin Pump Device
- Insulin Pump Reservoir
- Infusion Set
- Technology
- Insulin pens
- Cartridges in Reusable Pens
- Insulin Disposable Pens
- Insulin Syringes
- Jet Injectors
- Insulin Pump
- Monitoring Devices
- Self-monitoring Blood Glucose
- Glucometer Devices
- Blood Glucose Test Strips
- Lancets
- Continuous Glucose Monitoring
- Sensors
- Durables (Receivers and Transmitters)
- Self-monitoring Blood Glucose
- End User
- Hospital/Clinics
- Home/Personal
Data Sources, Market Sizing, and Validation
Desk Research
Desk research was used to set the market context and build the first structure of the model, before numbers were stress tested with interviews. We relied on public sources such as NHS and UK government health statistics, ONS demographic series, MHRA medical device guidance and alerts, and peer reviewed clinical journals that report adoption and outcomes for glucose monitoring and insulin delivery.
Along with that, we reviewed company annual reports, investor presentations, and trusted press coverage to understand product mix shifts and pricing direction. To fill gaps where public reporting is thin, we also used paid subscriptions for company financials and intelligence, plus patent database views to track innovation intensity in sensors, transmitters, and delivery systems. The desk sources listed here are illustrative only, since many other public documents and references were also used for collection, cross checks, and clarification.
Primary Interviews and Surveys
Primary work focused on validating what gets purchased and used in the UK, and how demand is split across home use versus hospital and clinic settings. We spoke with a mix of device manufacturers, distributors, clinicians, and diabetes care stakeholders across the UK to confirm adoption of SMBG versus CGM, replacement cycles, and typical pricing movements, and then used that input to triangulate assumptions that were unclear in desk findings.
Distribution of primary research fieldwork respondents
| Company type | Respondent position |
|---|---|
| Top tier: 27% | CXOs: 14% |
| Mid tier: 56% | Functional/Unit leaders: 32% |
| Smaller Players: 17% | Managers: 54% |
Market-Sizing & Forecasting
Sizing starts with a top-down demand pool build that ties device spend to treated diabetes populations in the UK and the typical monitoring and delivery pathways used in care. From there, revenues are reconstructed across management and monitoring devices using a small set of measurable inputs that are practical to defend on a client call.
Key inputs that guided the model included the diagnosed and treated diabetes population trend, CGM versus SMBG adoption share, sensor and transmitter replacement cycles, test strip usage frequency for SMBG users, and the installed base dynamics for insulin pumps and pens. Where public price points vary, we used interview backed average selling price ranges by device class, and then applied currency timing consistently to avoid mixing price years.
Forecasts were produced using scenario analysis built around adoption shifts (especially CGM uptake), reimbursement and access signals, and expected replacement patterns. We then reviewed the outputs against short historical growth using one pass of exponential smoothing to avoid over reacting to single year spikes. Selective bottom-up approximations were run as checks, such as sampled ASP times unit volume for sensors and strips, and distribution level channel checks for pump consumables. Where data gaps remained, we used conservative penetration ranges and then validated those ranges again through follow-up calls.
Data Validation & Update Cycle
Results are validated through triangulation across at least three angles. In practice, this usually means checking population based demand math, the pricing and replacement assumptions, and independent signals from interviews and public statistics. When a segment total looks off, variance checks are run by revisiting unit volumes, adoption shares, and any one-time events that could explain the move, and then the logic is reviewed by another analyst before sign off.
The model is refreshed annually so the base year and assumptions do not get stale, and interim updates are triggered when material events occur, such as major reimbursement changes or meaningful product transitions in CGM or pump technology. Before a report is delivered, a final pass is done to reflect the latest available public data and any new confirmation points collected from the field.
Mordor Intelligence's UK Diabetes Devices Market Size Versus Other Published Estimates
Published market values for UK diabetes devices often differ, even when the titles look similar. This usually comes from the counted product set and the way usage is converted into revenue, which can change from one publisher to another. Differences also show up when the base year is not aligned and when price and replacement assumptions are not updated at the same time.
Diabetes management mobile applications are included in some estimates, but they sit outside Mordor Intelligence's scope, which keeps the total focused on physical monitoring and insulin delivery devices with clear unit and replacement logic. Other gaps usually come from mixing broader diabetes care spending with device only revenue, using aggressive CGM adoption curves without reconciling sensor wear time and replacement frequency, or applying list prices instead of average realized pricing in the UK channel.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Mordor Intelligence | USD 89.98 M (2025) | |
| Industry Publisher A | USD 84.31 M (2024) | Uses a different base year and may apply an earlier pricing mix for CGM and pump consumables, which can shift the starting value even if device categories look similar. |
| Consultancy B | USD 800.00 M (2023) | Appears to broaden scope beyond devices by counting software apps alongside hardware, and the much larger total suggests wider diabetes care spending or category overlap that is not reconciled to unit replacement patterns. |
The spread across the three figures mainly reflects how tightly the product scope is defined and whether volumes are anchored to realistic UK replacement behavior. By keeping inputs traceable to demand pool, adoption share, and repeat purchase cycles, the resulting estimate is easier to replicate and explain when assumptions need to be updated.
Key Questions Answered in the Report
How big is the UK diabetes devices market?
The UK diabetes devices market size is expected to reach USD 95.95 million in 2026 and grow at a CAGR of 6.64% to reach USD 132.33 million by 2031.
What is the current UK diabetes devices market size?
In 2026, the UK diabetes devices market size is expected to reach USD 95.95 million.
Who are the key players in UK diabetes devices market?
Insulet Corporation, Roche Diabetes Care, Abbott Diabetes Care, Dexcom Inc. and Medtronic PLC are the major companies operating in the UK diabetes devices market.
What years does this UK diabetes devices market cover, and what was the market size in 2025?
In 2025, the UK diabetes devices market size was estimated at USD 95.95 million. The report covers the UK diabetes devices market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the UK diabetes devices market size for years: 2026, 2027, 2028, 2029, 2030 and 2031.
Page last updated on:
